StemCells, Inc. (NASDAQ: STEM) announced positive results from the first Phase I clinical trial of its proprietary HuCNS-SC product candidate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE